Beyond Air Reports Strong Revenue Growth and Strategic Advances

Beyond Air ( (XAIR) ) has released its Q4 earnings. Here is a breakdown of the information Beyond Air presented to its investors.

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company that focuses on utilizing nitric oxide to improve patient outcomes in respiratory and neurological conditions, as well as solid tumors. The company recently reported a significant 220% increase in annual revenue, reaching $3.7 million for the fiscal year ending March 31, 2025, compared to the previous year. This growth is attributed to the rising demand for its LungFit PH system, which is now operational in over 45 hospitals across the U.S. and has expanded internationally to Europe, Australia, and the Middle East.

The company’s financial performance highlights include an expected revenue of at least $1.7 million for the quarter ending June 30, 2025, and projected revenue guidance of $12 to $16 million for fiscal year 2026. Beyond Air has also made strategic advancements, such as submitting a PMA supplement for its second-generation LungFit PH to the FDA and securing international distribution partnerships that cover over 2 billion lives.

Beyond Air’s strategic initiatives include the appointment of Robert Goodman to its Board of Directors, enhancing its commercial focus. The company has also made significant progress in its pipeline, including ongoing clinical trials for its ultra-high concentration nitric oxide therapy for solid tumors and a new patent for treating non-tuberculous mycobacteria lung infections.

Despite a net loss of $46.6 million for the fiscal year, Beyond Air has reduced its operating expenses and continues to focus on expanding its market presence and product offerings. With a cash position of $6.9 million and additional financing secured, the company is poised for further growth.

Looking ahead, Beyond Air anticipates continued revenue growth and expansion of its LungFit systems, driven by regulatory approvals and increased market penetration. The company remains committed to advancing its innovative therapies and enhancing shareholder value.